05:28 AM EST, 01/24/2025 (MT Newswires) -- Allurion Technologies ( ALUR/WS ) shares surged more than 81% premarket Friday after the company said overnight that it plans to initiate a combination clinical study to improve muscle mass and overall body composition.

The clinical trial will combine the Allurion Program, a weight-loss platform, with GLP-1 agonists. The latter are primarily used to manage Type 2 diabetes and obesity.

The study aims to prove that, by combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy, patients can "lose significant weight while increasing muscle mass and improving overall body composition," Allurion ( ALUR/WS ) Chief Executive Shantanu Gaur said late Thursday.

Price: 6.73, Change: +3.03, Percent Change: +81.89